Endovasc buys women's health company
This article was originally published in Clinica
Endovasc has signed a non-binding letter of intent to acquire Israeli women's health company Intermed 2000. Drug delivery company Endovasc said that its experience with the "legacy of neglect" in the field of heart disease and other conditions affecting women, prompted the acquisition, for an undisclosed amount.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.